---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-001323"
form_type: "8-K"
ticker: "NRXS"
cik: "0001933567"
company_name: "Neuraxis, INC"
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T07:15:07.350138+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeurAxis preliminary Q4 revenue up 50% YoY to ~$800K; cash $3.7M

## Summary
- Preliminary Q4 2024 revenue ~$800K (+50% YoY); FY2024 revenue ~$2.7M (+11% YoY).
- Cash balance as of Dec 31, 2024 was ~$3.7 million.
- Insurance coverage expanded to ~45M lives, up from 4M a year ago.
- FDA 510(k) clearance for IB-Stim expanded to ages 8-21; new CPT code for PENFS.
- Commercialization of FDA-approved Rectal Expulsion Device (RED) begins Q1 2025.

## SEC filing metadata
- accession: 0001493152-25-001323
- form_type: 8-K
- ticker: NRXS
- cik: 0001933567
- company_name: Neuraxis, INC
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933567/000149315225001323/0001493152-25-001323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933567/000149315225001323/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-001323
- JSON: https://secwatch.observer/filing/0001493152-25-001323.json
- Plain text: https://secwatch.observer/filing/0001493152-25-001323.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.